This research is largely driven by early biomarker discoveries showing that many ME/CFS patients suffer from a deficiency in serum acylcarnitine, which directly impairs mitochondrial oxidative phosphorylation
In consideration of the multiple metabolic and cardiovascular effects seen in subjects treated with GLP-1RAs and SGLT-2is (e.g., reduction of hyperglycemia, weight loss, free/fat mass and bone remodeling, anti-atherosclerosis, natriuresis), it is reasonable to speculate that GH and IGF-1 may play a about a relevant role in this context
Also approved under the CNPV pilot, Foundayo is a once-daily, oral nonpeptide GLP-1 that requires dose titration to mitigate gastrointestinal side effects
However, unlike FDA-approved medications, compounded versions are not reviewed by the FDA for safety, effectiveness, or quality